Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005â2017
Schenfeld, Jennifer R, Bennett, Corina W, Li, Shuling, DeCosta, Lucy J, Jaramillo, Renee R, Gawade, Prasad LJournal:
Journal of Oncology Pharmacy Practice
DOI:
10.1177/1078155220915772
Date:
April, 2020
File:
PDF, 393 KB
2020